HM 97211
Alternative Names: HM97211Latest Information Update: 28 Apr 2023
Price :
$50 *
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Small cell lung cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in South Korea (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in South Korea (PO)
- 29 Mar 2019 Preclinical trials in Acute myeloid leukaemia in South Korea (PO) before March 2019